

PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (W), Mumbai (Maharashtra)

Statement of Consolidated Unaudited Financial Results for the Quarter and Nine Months ended 31st December 2012

PART - I							
Sr. No.	Particulars	Quarter ended 31/12/2012 Unaudited	Quarter ended 30/09/2012 Unaudited	Quarter ended 31/12/2011 Unaudited	Nine Months ended 31/12/2012 Unaudited	Nine Months ended 31/12/2011 Unaudited	(Rs in Lacs) Previous year ended 31/03/2012 Audited
1	Income from operation (a) Net Sales/Income from Operations (Net of Excise Duty)	6893.88	7239.25	9330.36	21292.61	25103.89	33251.00
	(b) Other Operating Income	3.21	12.00	44.40	18.38	147.26	43.91
	Total Income From Operation (Net)	6,897.09	7,251.25	9,374.76	21,310.99	25,251.15	33,294.91
2	Expenditure						
	a) Cost of Material Consumed	3911.29	4184.65	5852.99	11146.63	14317.20	17349.83
	b) Purchase of Stock In Trade						
	c) Change in Inventories of Finished Goods, Work in Progress and Stock In Trade	-112.98	-632.30	-1331.79	1380.58	-1248.91	1154.74
	d) Employee Benefit Expenses	507.54	652.99	559.09	1755.63	1693.24	2462.27
	e) Depreciation and Amortisation Expenses	583.69	564.32	337.31	1594.06	930.11	1446.78
	f) Other Expenditure (Any Item Exceeding 10% of the Total expenses relating to continuing operations to be shown separately)	2950.13	2806.30	2715.27	8444.70	7107.97	10892.60
	Total Expenses	7839.67	7575.95	8132.87	24321.60	22799.61	33306.22
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	(942.58)	(324.70)	1,241.89	(3,010.61)	2,451.54	(11.31)
4	Other Income	0.00	0.00	0.00	0.00	0.00	0.00
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	(942.58)	(324.70)	1,241.89	(3,010.61)	2,451.54	(11.31)
6	Finance costs	1585.27	1598.97	1178.01	4385.68	3269.92	4840.64
7	Profit/(Loss) from ordinary activities after finance costs but before Exceptional items (5-6)	(2,527.85)	(1,923.67)	63.88	(7,396.29)	(818.38)	(4,851.95)
8	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
9	Profit / (Loss) from ordinary activities before tax (7 + 8)	(2,527.85)	(1,923.67)	63.88	(7,396.29)	(818.38)	(4,851.95)
10	Tax Expenses	83.16	69.66	92.42	225.12	293.37	484.36
11	Net Profit / (Loss) from ordinary activities after tax (9 + 10)	(2,611.01)	(1,993.34)	(28.54)	(7,621.41)	(1,111.75)	(5,336.31)
12	Extraordinary items (net of tax expense Lakhs)						
13	Net Profit / (Loss) for the period (11 + 12)	(2,611.01)	(1,993.34)	(28.54)	(7,621.41)	(1,111.75)	(5,336.31)
14	Share of profit / (loss) of associates*						
15	Minority interest *						1.51
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 + 14 + 15) *	(2,611.01)	(1,993.34)	(28.54)	(7,621.41)	(1,111.75)	(5,337.82)
17	Paid-up equity share capital (Face Value of the Share shall be indicated)	2586.68	2586.68	2586.68	2586.68	2586.68	2586.68
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year						27080.12
19 i	Earnings per share (before extraordinary items) (of Rs 10/- each) (not annualised):						
	(a) Basic	(10.09)	(7.71)	(0.11)	(29.46)	(4.30)	(20.64)
	(b) Diluted	(10.09)	(7.71)	(0.11)	(29.46)	(4.30)	(20.64)
19 ii	Earnings per share (After extraordinary items) (of Rs 10/- each) (not annualised):						
	(a) Basic	(10.09)	(7.71)	(0.11)	(29.46)	(4.30)	(20.64)
	(b) Diluted	(10.09)	(7.71)	(0.11)	(29.46)	(4.30)	(20.64)

* Applicable in the case of consolidated results.

Note: The classification / disclosure of items in the financial results shall be in accordance with the Revised Schedule VI of the Companies Act, 1956

Further to the above, profit/loss from discontinuing operations, if any, included in the above shall be disclosed with details thereof.



PART -II

A PARTICULARS OF SHAREHOLDING							
1	Public Shareholding						
	Number of Shares	7,944,924	7,944,924	7,944,924	7,944,924	7,944,924	7,944,924
	Percentage of shareholding	30.71%	30.71%	30.71%	30.71%	30.71%	30.71%
2	Promoters and Promoter Group Shareholding **						
	a) Pledged/Encumbered						
	Number of shares	17,921,907	7,378,799	7,378,799	17,921,907	7,378,799	7,378,799
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00%	41.17%	41.17%	100.00%	41.17%	41.17%
	Percentage of Shares (as a % of the total share capital of the Company)	69.29%	28.53%	28.53%	69.29%	28.53%	28.53%
	b) Non-encumbered						
	Number of shares	-	10,543,108	10,543,108	-	10,543,108	10,543,108
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	-	58.83%	58.83%	-	58.83%	58.83%
	Percentage of Shares (as a % of the total share capital of the Company)	-	40.76%	40.76%	-	40.76%	40.76%
B	Detail of Investor Compliant	3 months ended (31.12.2012)					
	Pending at the beginning of the quarter	0					
	Received during the quarter	4					
	Disposed of during the quarter	4					
	Remaining unresolved at the end of the quarter	0					

NOTES

- The above results were reviewed by statutory auditors and audit committee of the company and approved by Board of Directors in their meeting held on 30th
- The Holding Company had approached the lender banks for restructuring of its loans with the CDR mechanism. The final package as approved by CDR EG has been finally implemented on 1st January 2013.
- The unaudited financial results of the subsidiary companies have been consolidated
- The Company is engaged in the Pharmaceuticals business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Accounting (AS-17).
- The previous year/period have been regrouped/rearranged wherever found necessary
- The standalone financial results of the company are available on the website of the company i.e. www.pdindia.com and on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com). The key standalone financial results are given below:

Sr. No	Particulars	Quarter ended	Quarter ended	Quarter ended	Nine months ended	Nine months ended	Year Ended
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
		31.12.2012	30.09.2012	31.12.2011	31.12.2012	31.12.2011	31.03.2012
1	Income from operations & other income	3,903.40	4,783.80	6,459.88	13,546.13	17,111.22	22,283.73
2	Profit/Loss before tax	-2,002.30	(1,573.41)	(7.42)	(6,578.05)	(1,126.28)	(4,320.16)
3	Profit/Loss after tax	-2,052.30	(1,623.41)	(59.17)	(6,728.05)	(1,281.53)	(4,781.60)

For and on behalf of Board of Directors

Place: Indore
Date: 30th January 2013



Vinod Kumar Gupta
Managing Director

PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office : 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (W), Mumbai (Maharashtra)

Statement of Standalone Unaudited Financial Results for the Quarter and Nine Months ended 31st December 2012

PART - I								(Rs in Lacs)
Sr. No.	Particulars	Quarter ended 31/12/2012 Unaudited	Quarter ended 30/09/2012 Unaudited	Quarter ended 31/12/2011 Unaudited	Nine Months ended 31/12/2012 Unaudited	Nine Months ended 31/12/2011 Unaudited	Previous year ended 31/03/2012 Audited	
1	(a) Net Sales/Income from Operations (Net of Excise Duty)	3901.19	4776.09	6424.64	13534.67	17042.34	22256.08	
	(b) Other Operating Income	2.21	7.71	35.24	11.46	68.88	27.65	
	Total Income From Operation (Net)	3,903.40	4,783.80	6,459.88	13,546.13	17,111.22	22,283.73	
2	Expenditure							
	a) Consumption of Material Consumed	1557.67	2364.85	4174.97	5395.97	9597.90	10696.92	
	b) Purchase of Stock In Trade							
	c) Change in Inventories of Finished Goods, Work in Progress and Stock In trade	267.25	-210.97	-1350.23	2318.84	-1280.24	739.62	
	d) Employee Benefit Expenses	449.98	519.73	463.33	1521.85	1370.71	1987.84	
	e) Depreciation and Amortisation Expenses	430.00	430.00	300.66	1290.00	820.16	1284.43	
	f) Other Expenditure (Any Item Exceeding 10% of the Total expenses relating to continuing operations to be shown separately	2016.48	2017.31	1894.05	6102.13	5010.77	7976.07	
	Total Expenses	4721.38	5120.92	5482.78	16628.79	15519.30	22684.88	
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	(817.98)	(337.12)	977.10	(3,082.66)	1,591.92	(401.15)	
4	Other Income	0.00	0.00	0.00	0.00	0.00	0.00	
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	(817.98)	(337.12)	977.10	(3,082.66)	1,591.92	(401.15)	
6	Finance costs	1184.32	1236.29	984.52	3495.39	2718.20	3919.01	
7	Profit after Interest but before Exceptional items (5-6)	(2,002.30)	(1,573.41)	(7.42)	(6,578.05)	(1,126.28)	(4,320.16)	
8	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00	
9	Profit / (Loss) from ordinary activities before tax	(2,002.30)	(1,573.41)	(7.42)	(6,578.05)	(1,126.28)	(4,320.16)	
10	Tax Expenses	50.00	50.00	51.75	150.00	155.25	461.44	
11	Net Profit / (Loss) from ordinary activities after tax (9 + 10)	(2,052.30)	(1,623.41)	(59.17)	(6,728.05)	(1,281.53)	(4,781.60)	
12	Extraordinary items (net of tax expense) Lakhs)						0.00	
13	Net Profit / (Loss) for the period (11 + 12)	(2,052.30)	(1,623.41)	(59.17)	(6,728.05)	(1,281.53)	(4,781.60)	
14	Share of profit / (loss) of associates*							
15	Minority interest *							
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 + 14 + 15) *	(2,052.30)	(1,623.41)	(59.17)	(6,728.05)	(1,281.53)	(4,781.60)	
17	Paid-up equity share capital (Face Value of the Share shall be indicated)	2586.68	2586.68	2586.68	2586.68	2586.68	2586.68	
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year						22698.33	
19 i	Earnings per share (before extraordinary items) (of Rs 10/- each) (not annualised):							
	(a) Basic	(7.93)	(6.28)	(0.23)	(26.01)	(4.95)	(18.49)	
	(b) Diluted	(7.93)	(6.28)	(0.23)	(26.01)	(4.95)	(18.49)	
19 ii	Earnings per share (After extraordinary items) (of Rs 10/- each) (not annualised):							
	(a) Basic	(7.93)	(6.28)	(0.23)	(26.01)	(4.95)	(18.49)	
	(b) Diluted	(7.93)	(6.28)	(0.23)	(26.01)	(4.95)	(18.49)	

* Applicable in the case of consolidated results.

Note. The classification / disclosure of items in the financial results shall be in accordance with the Revised Schedule VI of the Companies Act, 1956.

Further to the above, profit/loss from discontinuing operations, if any, included in the above shall be disclosed with details thereof.



PART -II

A PARTICULARS OF SHAREHOLDING

1	Public Shareholding						
	-No. of Shares	7,944,924	7,944,924	7,944,924	7,944,924	7,944,924	7,944,924
	-Percentage of shareholding	30.71%	30.71%	30.71%	30.71%	30.71%	30.71%
2	Promoters and Promoter Group Shareholding **						
	a) Pledged/Encumbered						
	-No. of shares	17,921,907	7,378,799	7,378,799	17,921,907	7,378,799	7,378,799
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00%	41.17%	41.17%	100.00%	41.17%	41.17%
	-Percentage of Shares (as a % of the total share capital of the Company)	69.29%	28.53%	28.53%	69.29%	28.53%	28.53%
	b) Non-encumbered						
	-No. of shares	-	10,543,108	10,543,108	-	10,543,108	10,543,108
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)		58.83%	58.83%		58.83%	58.83%
	-Percentage of Shares (as a % of the total share capital of the Company)		40.76%	40.76%		40.76%	40.76%
B	Detail of Investor Compliant						
	Pending at the beginning of the quarter			0			
	Received during the quarter			4			
	Disposed of during the quarter			4			
	Remaining unresolved at the end of the quarter			0			

NOTES :

- The above results were reviewed by statutory auditors and audit committee of the company and approved by Board of Directors in their meeting held on 30th January 2013.
- The Company had approached the lender banks for restructuring of its loans with the CDR mechanism. The final package as approved by CDR EG has been finally implemented on 1st January 2013.
- The Company is engaged in the Pharmaceuticals business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Accounting (AS-17).
- The previous year/period have been regrouped/rearranged wherever found necessary.
- The standalone financial results of the company are available on the website of the company i.e. www.pdindia.com and on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com). The key standalone financial results are given below:

For and on behalf of Board of Directors

Place: Indore
Date: 30th January 2013



Vinod Kumar Gupta
Managing Director